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Abstract Lung surfactant protein C (SP-C) is a lipopeptide
that contains two fatty acyl (palmitoyl) chains bound via
intrinsically labile thioester bonds. SP-C can transform from a
monomeric K-helix into L-sheet aggregates, reminiscent of
structural changes that are supposed to occur in amyloid fibril
formation. SP-C is here shown to form amyloid upon incubation
in solution. Furthermore, one patient with pulmonary alveolar
proteinosis (PAP, a rare disease where lung surfactant proteins
and lipids accumulate in the airspaces) and six healthy controls
have been studied regarding presence and composition of amyloid
fibrils in the cell-free fraction of bronchoalveolar lavage (BAL)
fluid. Abundant amyloid fibrils were found in BAL fluid from the
patient with PAP and, in low amounts, in three of the six healthy
controls. SDS-insoluble fibrillar material associated with PAP
mainly consists of SP-C, in contrast to the fibrils found in
controls. Fibrillated SP-C has to a significant extent lost the
palmitoyl groups, and removal of the palmitoyl groups in vitro
increases the rate of fibril formation.
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1. Introduction
Amyloid ¢bril formation is associated with neurodegenera-
tive disease and systemic amyloidosis. The amyloid-related
proteins are constitutively present in their soluble state, but
form insoluble aggregates under some conditions [1]. In spite
of close structural similarities of the ¢brils found in di¡erent
amyloid diseases, the proteins or peptides forming the amy-
loid lack structural similarities in their native states, which
indicates that ¢brils can be formed via di¡erent pathways.
Some mutant amyloid-forming proteins are signi¢cantly de-
stabilized compared to the corresponding non-amyloidogenic
wild-type forms, indicating that intrinsic protein stability is
one important factor in amyloid formation [2]. For most amy-
loid-associated proteins, however, no clear-cut reason for un-
folding and amyloid formation is known [3].
Pulmonary surfactant is essential for normal respiration by
lowering the alveolar surface tension and by contributing to
pulmonary host-defence. Four surfactant-associated proteins
are known, SP-A, SP-B, SP-C and SP-D, whereof only SP-C
appears to be uniquely expressed in the lungs [4,5]. SP-C is a
transmembrane 35-residue lipopeptide in which amino acid
residues 9^34 form an K-helix [6]. SP-C is one of the most
hydrophobic naturally occurring peptides known; the human
molecule contains 28 residues with aliphatic side-chains, in-
cluding two palmitoyl chains bound to Cys-5 and Cys-6 via
thioester bonds, which are labile and are readily cleaved by
nucleophilic agents [7]. SP-C in solution transforms from a
monomeric K-helix into aggregates with L-sheet conformation.
In contrast, SP-C is thermodynamically stable and remains
helical in lipid membranes [8]. The K-helix to L-sheet conver-
sion of SP-C resembles the structural transitions which have
been reported to take place in many proteins and peptides
associated with amyloid formation [9]. Initial studies con-
¢rmed that SP-C, dissolved in chloroform/methanol/0.1 M
HCl or ethanol (about 100 WM) and incubated at 37‡C, forms
elongated ¢brils with a diameter of 2^4 nm, thus exhibiting
amyloid-like appearance (unpublished data). This prompted
us to further investigate SP-C ¢bril formation.
PAP is an uncommon lung disease in which lipoproteina-
ceous material is accumulated within the airspaces of other-
wise preserved alveolar lung tissue, causing impaired gas ex-
change and dyspnea [10]. PAP can occur as a secondary event
to lung infections, hematologic malignancies, and after expo-
sure to inhaled chemicals and minerals, but many cases of
PAP are idiopathic [11]. Mice with severe combined immuno-
de¢ciency and mice de¢cient in the granulocyte macrophage
colony-stimulating factor (GM-CSF), or its receptor, show
alveolar accumulation of surfactant proteins and lipids similar
to that of human PAP [12^14]. The PAP-like changes in GM-
CSF de¢cient mice can be reversed by administration of aero-
solized GM-CSF [15,16].
2. Materials and methods
2.1. Handling of BAL £uid
The PAP patient was diagnosed by lung histology and electron
microscopy. He had no other diseases and was on no treatment.
Lung lavage was performed because of progressive dyspnea and hy-
poxemia. BAL £uid from six healthy volunteers (three men and three
women, age 18 to 49 years) were used as controls. Bronchoalveolar
lavage £uid was obtained by instillation of sterile saline, and subse-
quent gentle aspiration (approved by ethical committee). The BAL
£uid collected was ¢rst centrifuged at 150Ug for 15 min to remove
cells and debris. Subsequently the supernatant was centrifuged at
20 000Ug for 2 h at 4‡C, and the resulting pellet was equilibrated
in 5 mM Tris-HCl, 100 mM NaCl, pH 7.4, 1.64 M NaBr and centri-
fuged at 100 000Ug for 4 h at 4‡C. The pellets obtained after 20 000
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and 100 000Ug centrifugation were washed with distilled water and
used for further analyses.
2.2. Isolation of SDS-insoluble aggregates
Equal amounts (typically 2^5 mg) of the PAP and control pellets
were suspended in 1% (w/v) SDS by vortexing, and centrifuged for 20
min at 100 000Ug at 20‡C [17]. After removal of the supernatant, the
same procedure was repeated four times. The SDS-insoluble pellets
were analyzed by SDS-PAGE, polarization microscopy after staining
with Congo red, and electron microscopy. The SDS-soluble superna-
tants were lyophilized and analyzed by SDS-PAGE.
2.3. SDS-PAGE and amino acid sequence analysis
Samples were solubilized in 4% (w/v) SDS/45 mM Tris-HCl, pH
8.3, with or without 5% (v/v) L-mercaptoethanol, by incubation for 10
min at 110‡C. Electrophoresis was performed in 10^20% gradient
Tricine gels with 0.1% SDS in the running bu¡er. Gels were stained
with Coomassie brilliant blue or silver. Alternatively, proteins were
electro-transferred from the electrophoresis gels to polyvinyledinedi-
£uoride (PVDF) membranes at 25 V for 100 min at room temper-
ature. After staining of the PVDF membrane, bands were excised and
analyzed for N-terminal amino acid sequence by Edman degradation
in an Applied Biosystems 494 cLC protein sequencer with on-line
HPLC for detection of phenylthiohydantoin derivatives. Western blot-
ting was performed after protein transfer to PVDF membranes by
using an alkaline phosphatase-labelled monoclonal anti-human IgG
antibody.
2.4. Analysis of SP-C ¢bril formation
Chemical depalmitoylation of SP-C [7] was performed by treating
the peptide, dissolved in chloroform/methanol, 1:2 (v/v), with trimeth-
ylamine for 1.5 h at room temperature, whereafter equimolar
amounts, relative to trimethylamine, of tri£uoroacetic acid were
added. The removal of both palmitoyl chains was con¢rmed by
mass spectrometry [18].
For ¢brillation studies, 100 WM of native SP-C or depalmitoylated
SP-C in chloroform/methanol/0.1 M HCl, 32:64:5 (by vol) or ethanol
was incubated at 37‡C. After di¡erent time intervals, aliquots were
removed and centrifuged at 20 000Ug for 20 min at 22‡C [19]. The
supernatants were analyzed by amino acid analysis for determination
of peptide content, and the pellets were analyzed by electron micros-
copy.
2.5. Light microscopy after staining with Congo red
Staining was performed essentially as described [20]. Brie£y, SDS-
insoluble aggregates were suspended in 50 Wl phosphate-bu¡ered sal-
ine by sonication before addition of 10 Wl Congo red (2%, w/v).
Samples were incubated for 1 h at ambient temperature and aggre-
gated proteins were collected by centrifugation at 13 000Ug, for 5 min.
The aggregates were washed twice with 100 Wl of water before resus-
pension in 50 Wl of water. Ten Wl of the suspension was placed on a
glass slide and allowed to dry. Samples were viewed by polarization
microscopy using a Zeiss Axialfold microscope.
2.6. Electron microscopy
The pellets obtained after centrifugation of BAL, SDS extractions,
or after incubation of SP-C or depalmitoylated SP-C in solution were
suspended in a small volume of water by low-energy sonication for 5 s.
Aliquots of 8 Wl were placed on grids covered by a carbon-stabilized
formvar ¢lm. Excess £uid was withdrawn after 30 s, and after air-
drying the grids were negatively stained with 3% uranyl acetate in
water. The stained grids were examined and photographed in a Philips
CM120TWIN electron microscope operated at 80 kV.
3. Results
3.1. Amyloid ¢brils in BAL £uid
Alveolar contents from one PAP patient and six healthy
controls were recovered by bronchoalveolar lavage. After re-
moval of cells and coarse debris, a particulate fraction was
obtained after ultracentrifugation. Electron microscopy re-
vealed the presence of signi¢cant amounts of amyloid ¢brils
in the pellet from the PAP patient (Fig. 1A). In three of the
six control subjects, ¢brils of similar appearance could be
detected, but they were much less abundant than in the
PAP case. The pellet from the PAP patient was then sus-
pended in 1% SDS and centrifuged at 100 000Ug for 20
min. The supernatant was removed and the resuspension
and centrifugation procedure was repeated four times for
the pellet. This procedure readily removes soluble proteins
and has previously been used for isolation of the Alzheimer
amyloid beta (AL) peptide from brain tissue [17]. The ¢nal
pellet obtained was analyzed for ultrastructural properties,
Fig. 1. Amyloid ¢brils are present in pulmonary alveolar proteino-
sis. Cell-free BAL £uid from a PAP patient was pelleted and ana-
lyzed by electron microscopy (A), and further extracted ¢ve times
with 1% SDS, whereafter the insoluble pellet was analyzed by elec-
tron microscopy (B). Bar = 100 nm.
Fig. 2. Tinctorial properties of isolated ¢brils. Congo red birefrin-
gence of SDS-insoluble pellet from PAP BAL £uid. Protein aggre-
gates were stained with Congo red, washed and applied to micro-
scope slides and observed by bright ¢eld microscopy (A) or by
polarization microscopy (B). Magni¢cation 360U.
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which revealed ¢brillar structures with amyloid appearance
(Fig. 1B), that stain with Congo-red and exhibit green bire-
fringence (Fig. 2). This con¢rms that amyloid ¢brils are abun-
dant in PAP. In contrast, SDS extraction of the control sam-
ples yielded only a very faint pellet.
3.2. Amyloid ¢bril protein composition
In order to de¢ne the constituent proteins of the PAP al-
veolar amyloid, the pellet obtained by 1% SDS extraction was
resolved by SDS-PAGE under reducing conditions, followed
by sequence analysis and Western blotting. This showed one
strong band at about 4 kDa and one band at about 8 kDa,
corresponding to monomeric and dimeric SP-C, respectively,
as well as one weaker band at 50 kDa, corresponding to IgG
heavy chain (Fig. 3, lane 1). The same analysis of the SDS-
soluble supernatant obtained from PAP alveolar material
identi¢ed several abundant proteins (Fig. 3, lane 2), i.e. albu-
min (65 kDa), SP-A (35 kDa), IgG light chain (25 kDa), and
SP-B (10 kDa), and weak bands corresponding to SP-C are
seen. In the healthy control, in sharp contrast, the SDS-in-
soluble pellet contains no detectable SP-C (Fig. 3, lane 3), but
SP-C and the other surfactant proteins are found exclusively
in the SDS-soluble supernatant (Fig. 3, lanes 4 and 5). SDS-
PAGE of the SDS-insoluble pellets from all healthy controls
con¢rmed that signi¢cant amounts of aggregated SP-C are
speci¢c for PAP (data not shown).
3.3. Importance of SP-C palmitoyl groups for ¢bril formation
SDS-PAGE of the PAP SDS-insoluble pellet without disul-
phide reduction revealed no SP-C bands, since the aggregates
did not enter the gel. However, native SDS-soluble SP-C mi-
grates as a monomer without disulphide reduction (Fig. 3,
lane 5). Consequently, SP-C aggregates in the 1% SDS-insolu-
ble pellet are disulphide-dependent. Since SP-C contains only
two cysteines which both normally are palmitoylated, the SP-
C population that forms SDS-insoluble disulphide-dependent
aggregates must contain depalmitoylated peptides. The exact
ratio of SP-C and depalmitoylated SP-C in the ¢brils cannot
be determined from the present data. However, a major part
of the ¢brillated material likely consists of depalmitoylated
SP-C, since no electrophoretic bands corresponding to SP-C
can be detected without disulphide reduction, and no detect-
able protein remains in the gel loading pocket with reduction.
Consistent with the assignment of depalmitoylated SP-C to
alveolar ¢brils, chemical depalmitoylation of SP-C increases
the rate of SP-C ¢bril formation in vitro (Fig. 4). Intriguingly,
electron microscopy indicates that ¢brils are formed from the
depalmitoylated peptide as early as 1.5 h after starting the
incubation (Fig. 4A). Moreover, determination of the amount
peptide that remains in solution after 5 and 15 days of incu-
bation con¢rms an increased rate of peptide aggregation after
removal of the palmitoyl groups (Fig. 4B).
4. Discussion
SP-C is here shown to form amyloid ¢brils. This could be
anticipated from its tendency to undergo KCL transitions [8].
The present data further indicate that amyloid formation can
occur in PAP (Figs. 1 and 2). The ¢brils associated with PAP
Fig. 3. Composition of PAP-associated insoluble ¢brils. SDS-PAGE
of proteins in BAL £uid which are insoluble (lanes 1 and 3) or solu-
ble (lanes 2, 4, 5) after ¢ve extractions with 1% SDS. The samples
were derived from a PAP patient (lanes 1 and 2) and a healthy con-
trol (lanes 3^5). The sample in lane 1 is the same material as ana-
lyzed in Figs. 1B and 2. The sample in lane 5 was not reduced,
while samples in lanes 1^4 were reduced. The identity of the di¡er-
ent bands, as deduced from amino acid sequence analysis or West-
ern blotting, are given to the left. The lane marked M shows the
migration of molecular size markers with indicated masses in kDa.
Fig. 4. Removal of SP-C palmitoyl groups increases ¢bril formation.
A: Electron micrograph of ¢brils formed after 1.5 h incubation of
depalmitoylated SP-C in chloroform/methanol/0.1 M HCl, 32:64:5
(by vol). Bar = 100 nm. B: Peptide amounts in solution after 5 and
15 days of incubation of native SP-C (open bars) and depalmitoy-
lated SP-C (¢lled bars).
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are composed of SP-C, depalmitoylated SP-C and IgG heavy
chain. The relative amounts of these proteins suggest that SP-
C peptides are the main constituents (Fig. 3). Previously it has
been shown that SP-A forms oligomeric aggregates in PAP
[21], but no SP-A could now be detected in the insoluble
¢brils (Fig. 3). We conclude that SP-C is the only surfactant
protein present in PAP amyloid. The etiology of PAP is
largely unknown, but decreased removal of the alveolar con-
tents by alveolar macrophages appears to be a common de-
nominator [22,23]. In GM-CSF knockout mice, as well as in
SP-D knockout mice, the alveolar macrophages have been
reported to be loaded with lipoproteinaceous material
[13,24,25]. The clearance of alveolar SP-C ¢brils is expected
to be signi¢cantly impaired compared to that of native SP-C,
since already dimeric/depalmitoylated SP-C is cleared from
mouse lungs with a half-life which is more than twice that
for monomeric/native SP-C [26]. Clearance of surfactant
phospholipids and SP-A is, however, also impaired in PAP
[27,28]. Alveolar accumulation of ¢brils may be toxic; AL
¢brils associated with Alzheimer’s disease induce oxidative
stress in microglial cells via binding to class A scavenger re-
ceptors [29]. It remains to be established whether alveolar
macrophages could be a¡ected by ¢brils in an analogous man-
ner. Notably, it has recently been shown that dimeric SP-C is
toxic to alveolar macrophages through increased formation of
superoxide anions [30].
Recent data indicate that amyloid formation in vitro is not
restricted to a limited set of proteins. This implies that the
development of amyloid diseases is governed by factors that
in£uence the equilibria between di¡erent conformational
states of amyloidogenic proteins [1,31]. The nature of these
factors is to a large extent unknown, but protein concentra-
tion a¡ects amyloid development [32]. Increased alveolar lev-
els of surfactant proteins (including SP-C) [33,34], likely con-
tribute to the formation of amyloid ¢brils in PAP. In
addition, removal of SP-C palmitoyl groups may in£uence
amyloid formation. Fibrils formed in PAP contain disul-
phide-linked depalmitoylated SP-C (Fig. 3), and depalmitoy-
lated SP-C is more prone to form ¢brils (Fig. 4). Previous
studies have revealed elevated levels of depalmitoylated forms
of SP-C in PAP compared to healthy controls [26,35]. Protein
palmitoylation often occurs in integral membrane proteins
close to their transmembrane helices [36], but the biological
function of this modi¢cation is not known. Depalmitoylation
apparently destabilizes the SP-C K-helix [6]. Removal of the
palmitoyl groups could therefore promote ¢brillation directly
by facilitating K-helix to L-sheet conversion. Moreover, depal-
mitoylation may induce ¢brillation indirectly, by favoring the
removal of SP-C from a lipid membrane where it is structur-
ally stable [8], in contrast to the situation in solution (Fig. 4).
In this context it is interesting to note that the AL peptide
associated with Alzheimer’s disease transforms into amyloid
¢brils if it is removed from its membrane-associated precursor
state [37]. No explanation for the observed loss of SP-C pal-
mitoyl groups in PAP is presently available. Cleavage of thio-
ester-linked acyl groups could be mediated by reactive oxygen
species, such as hydrogen peroxide, superoxide anions and
hypochlorite released from in£ammatory cells [38]. Release
of agents that cleave SP-C-linked palmitoyl chains, combined
with disrupted removal of surfactant by alveolar phagocytes,
could thus cause an exponential growth of amyloid ¢brils. It
should be pointed out, however, that the production of reac-
tive oxygen species is decreased in GM-CSF null mice [39].
Further studies are motivated in order to assess the role of
amyloid ¢brils, and the importance of in£ammatory cells and
surfactant clearance in the pathogenesis of alveolar proteino-
sis.
The K-helix of SP-C is metastable in solution [8]. As
pointed out previously [8,40] the long poly-Val segment of
SP-C statistically favors L-sheet conformation over helix for-
mation. It is reasonable to believe that this K/L discordance
underlies structural transition and ¢bril formation by SP-C,
and we suggest that also other amyloid-forming proteins may
contain K-helices with high statistical propensity for L-sheet
formation.
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